January 9, 2018

Melinta completes $270M antibiotics acquisition

Photo | Contributed
Photo | Contributed
Melinta Therapeutics CEO Dan Wechsler

New Haven's Melinta Therapeutics Inc., which is preparing for the commercial launch of its recently approved MRSA antibiotic Baxdela, said Monday it has completed its acquisition of a New Jersey drug company's infectious disease business.

Melinta first announced it would pay $270 million to acquire the business – including three drugs that have already gone to market – from The Medicines Company last November, saying the move would shore up its antibiotic portfolio and commercial team.

Melinta is developing antibiotics to treat serious bacterial infections, including Methicillin-resistant Staphylococcus aureus, commonly known as MRSA.

As a result of the deal closing, Melinta's portfolio now also includes The Medicines Company's urinary tract infection drug Vabomere, as well as Orbactiv, which treats acute bacterial skin and skin structure infections (ABSSSI) and Minocin IV, which treats hospital-related infections.

Peak sales potential of the four-drug portfolio, including Baxdela, exceeds $1 billion, Melinta said.

The drugmaker also announced Monday it has appointed The Medicines Company's Mike McGuire as senior vice president, commercial, noting his more than 25 years of experience in launching and commercializing antibiotics. McGuire replaces Melinta Chief Commercial Officer John Temperato, who the company said left to pursue other opportunities.

Melinta merged with publicly traded North Carolina antibiotics developer Cempra Inc. last November.

Natalie Missakian can be reached at news@newhavenbiz.com

Free E-Newsletter

Sign up now for our New Haven Biz
e-newsletter! Click Here

Subscribe to print for free

Premier issue coming in October. Click here to subscribe

Copyright 2018 New England Business Media